Thus, inhibition of the critical immune checkpoint blockers to restore CD8+ T cell cytotoxic activity should be sufficient to negatively impact MPNST development, particularly in NF1 patients (over patients with sporadic MPNST). Here, CD8A is linked to malignant peripheral nerve sheath tumor.